Holen Sie sich die Stockscreener-App
113.81
0.40%
0.45
Handel nachbörslich:
114.25
0.44
+0.39%
Schlusskurs vom Vortag:
$113.36
Offen:
$114.7
24-Stunden-Volumen:
1.56M
Relative Volume:
0.95
Marktkapitalisierung:
$22.74B
Einnahmen:
$5.36B
Nettoeinkommen (Verlust:
$1.43B
KGV:
16.09
EPS:
7.0718
Netto-Cashflow:
$1.42B
1W Leistung:
+4.93%
1M Leistung:
+19.06%
6M Leistung:
+15.23%
1J Leistung:
+65.59%
1-Tages-Spanne:
$113.31
$116.00
1-Wochen-Bereich:
$106.48
$116.00
52-Wochen-Spanne:
$66.85
$116.00
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
113.81 | 22.65B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
498.01 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
624.72 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
909.50 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.67 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.51 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-02-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-01-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-11-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Eingeleitet | Barclays | Overweight |
| 2025-06-16 | Hochstufung | Stifel | Hold → Buy |
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte (INCY): Truist Raises the Price Target to $105 as a Government Settlement Adds $246 Million to Net Sales - Insider Monkey
Incyte Corp gains 16% in a week, boosted by str... - Pluang
Incyte stock: Is INCY outperforming the healthcare sector? - MSN
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura - Yahoo Finance
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains? - Yahoo Finance
H.C. Wainwright reiterates Incyte stock rating on EU label expansion By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Incyte stock rating on EU label expansion - Investing.com
INCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
Incyte (INCY) Stock After 66% One-Year Rally Is The Market Too Optimistic Now - Yahoo Finance
Incyte (INCY) Wins EU Backing For Opzelura As Pipeline Data Builds Across Four Drugs - Yahoo Finance
INCY Maintains by UBS -- Price Target Raised to $113 - GuruFocus
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
UBS raises Incyte stock price target to $113 on biotech recovery By Investing.com - Investing.com Australia
UBS raises Incyte stock price target to $113 on biotech recovery - Investing.com Nigeria
Why is Incyte stock surging today? - Investing.com
Incyte receives positive CHMP opinion for Opzelura in moderate atopic dermatitis - grafa.com
Incyte (INCY) Receives Positive CHMP Opinion for Opzelura Approval - GuruFocus
Incyte Corporation stock hits 52-week high at 112.32 USD - Investing.com
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis - BioSpace
Incyte stock jumps on positive EU review for eczema cream - Investing.com
Star Therapeutics' bleeding-disorder drug VGA039 gets full Phase 1/2 data spotlight - Stock Titan
(ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis - Business Wire
Incyte Corp (INCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Incyte extends hematology data at EHA, shares track NASDAQ biotech peers - Ad-hoc-news.de
Japan Approves Incyte Lymphoma Therapy, Expanding DLBCL Options - MyChesCo
INCY Reiterates by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on Medicaid settlement - Investing.com
H.C. Wainwright reiterates Incyte stock rating on Medicaid settlement By Investing.com - Investing.com Canada
Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more - MSN
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT - MSN
INCY Maintained by Truist Securities -- Price Target Raised to $105 - GuruFocus
This ConocoPhillips Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Sahm
Truist raises Incyte stock price target to $105 on VWD outlook - Investing.com UK
Incyte reports tafasitamab combo benefit in Phase III FrontMIND study - MSN
Incyte Corporation’s Stock Price Soars to $103.66, Marking a Robust 5.54% Uptick - Smartkarma
Why is Incyte stock gaining today? - Investing.com
Incyte Corporation (INCY) Reaches Settlement with CMS Over Medic - GuruFocus
INCY Upgraded by BMO Capital -- Price Target Raised to $94.00 - GuruFocus
Incyte settles Medicaid rebate litigation with CMS, expects $246 million benefit - Investing.com
Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules - StreetInsider
Incyte reaches CMS settlement, to record $246M non-cash benefit after Opzelura ruling - TradingView
BMO upgrades Incyte stock rating on strategic progress By Investing.com - Investing.com South Africa
Incyte Stock: Is INCY Outperforming the Healthcare Sector? - Barchart.com
BMO upgrades Incyte stock rating on strategic progress - Investing.com
Incyte (INCY) Secures Approval for Minjuvi in Japan - GuruFocus
Incyte Trial Data Support New First-Line Approach in Lymphoma - MyChesCo
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):